Insulet Corporation vs Medtronic plc.
A head-to-head of Insulet Corporation (PODD) and Medtronic plc. (MDT) across valuation, profitability, growth, and dividends. Green marks the more favourable value on that metric only — not a recommendation.
| Metric | PODD | MDT |
|---|---|---|
| Market Cap | $11.36B | $106.50B |
| P/E (TTM) | 38.15 | 22.31 |
| Forward P/E | 19.87 | 12.38 |
| P/S | 3.83 | 2.83 |
| P/B | 8.91 | 2.13 |
| EV/EBITDA | 19.65 | 12.19 |
| Dividend Yield | — | 3.42% |
| Profit Margin | 10.44% | 13.20% |
| Gross Margin | 71.63% | 65.02% |
| Operating Margin | 17.50% | 18.78% |
| Revenue Growth (YoY) | +33.87% | +9.86% |
| FCF Yield | 3.49% | 5.25% |
| Debt / Equity | 72.79 | 55.72 |
| Current Ratio | 2.49 | 2.13 |
Which is better: Insulet Corporation or Medtronic plc.?
- ✓Larger by market cap: Medtronic plc.
- ✓Cheaper valuation (lower P/E): Medtronic plc.
- ✓More profitable (net margin): Medtronic plc.
- ✓Faster revenue growth: Insulet Corporation
- ✓Higher free-cash-flow yield: Medtronic plc.
Across 12 available metrics, Medtronic plc. leads 9–3.
There's no single "better" — it depends on your goal: income investors may prefer the higher yield, growth investors the faster grower, and value investors the cheaper one. See each stock's page for deeper detail. This is an automated read, not a recommendation.
Share:
This comparison is for informational and educational purposes only, based on available data — not a recommendation to buy or sell any stock.